Unexpected CK2β-antagonistic functionality of bisubstrate inhibitors targeting protein kinase CK2. 2020

Markus Pietsch, and Kaido Viht, and Alexander Schnitzler, and Ramesh Ekambaram, and Michaela Steinkrüger, and Erki Enkvist, and Christian Nienberg, and Anna Nickelsen, and Miriam Lauwers, and Joachim Jose, and Asko Uri, and Karsten Niefind
Institut II für Pharmakologie, Zentrum für Pharmakologie, Medizinische Fakultät, Universität zu Köln, Gleueler Str. 24, D-50931 Köln, Germany.

Protein kinase CK2, a heterotetrameric holoenzyme composed of two catalytic chains (CK2α) attached to a homodimer of regulatory subunits (CK2β), is a target for drug development for cancer therapy. Here, we describe the tetraiodobenzimidazole derivative ARC-3140, a bisubstrate inhibitor addressing the ATP site and the substrate-binding site of CK2 with extraordinary affinity (Ki = 84 pM). In a crystal structure of ARC-3140 in complex with CK2α, three copies of the inhibitor are visible, one of them at the CK2β interface of CK2α. Subsequent interaction studies based on microscale thermophoresis and fluorescence anisotropy changes revealed a significant impact of ARC-3140 and of its tetrabromo equivalent ARC-1502 on the CK2α/CK2β interaction. A structural inspection revealed that ARC-3140, unlike CK2β antagonists described so far, interferes with both sub-interfaces of the bipartite CK2α/CK2β interaction. Thus, ARC-3140 is a lead for the further development of highly effective compounds perturbating the quaternary structure of the CK2α2β2 holoenzyme.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001562 Benzimidazoles Compounds with a BENZENE fused to IMIDAZOLES.
D047390 Casein Kinase II A ubiquitous casein kinase that is comprised of two distinct catalytic subunits and dimeric regulatory subunit. Casein kinase II has been shown to phosphorylate a large number of substrates, many of which are proteins involved in the regulation of gene expression. Casein Kinase 2,Casein Kinase 2 alpha Subunit,Casein Kinase 2 alpha' Subunit,Casein Kinase 2 beta Subunit,Casein Kinase 2alpha,Casein Kinase 2alpha',Casein Kinase TS,Casein Kinase-2,Protein Kinase CK2,Protein Kinase CKII,2alpha', Casein Kinase,Kinase 2alpha', Casein,Kinase CKII, Protein
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D054879 Halogenation Covalent attachment of HALOGENS to other compounds. Bromination,Chlorination,Fluorination,Iodination,Iodation
D055503 Protein Multimerization The assembly of the QUATERNARY PROTEIN STRUCTURE of multimeric proteins (MULTIPROTEIN COMPLEXES) from their composite PROTEIN SUBUNITS. Protein Dimerization,Protein Heteromultimerizaton,Protein Multimer Assembly,Protein Trimerization,Assembly, Protein Multimer,Dimerization, Protein,Heteromultimerizaton, Protein,Heteromultimerizatons, Protein,Multimer Assembly, Protein,Multimerization, Protein,Trimerization, Protein
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking
D018360 Crystallography, X-Ray The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) X-Ray Crystallography,Crystallography, X Ray,Crystallography, Xray,X Ray Crystallography,Xray Crystallography,Crystallographies, X Ray,X Ray Crystallographies
D020134 Catalytic Domain The region of an enzyme that interacts with its substrate to cause the enzymatic reaction. Active Site,Catalytic Core,Catalytic Region,Catalytic Site,Catalytic Subunit,Reactive Site,Active Sites,Catalytic Cores,Catalytic Domains,Catalytic Regions,Catalytic Sites,Catalytic Subunits,Core, Catalytic,Cores, Catalytic,Domain, Catalytic,Domains, Catalytic,Reactive Sites,Region, Catalytic,Regions, Catalytic,Site, Active,Site, Catalytic,Site, Reactive,Sites, Active,Sites, Catalytic,Sites, Reactive,Subunit, Catalytic,Subunits, Catalytic
D020836 Protein Structure, Quaternary The characteristic 3-dimensional shape and arrangement of multimeric proteins (aggregates of more than one polypeptide chain). Quaternary Protein Structure,Protein Structures, Quaternary,Quaternary Protein Structures

Related Publications

Markus Pietsch, and Kaido Viht, and Alexander Schnitzler, and Ramesh Ekambaram, and Michaela Steinkrüger, and Erki Enkvist, and Christian Nienberg, and Anna Nickelsen, and Miriam Lauwers, and Joachim Jose, and Asko Uri, and Karsten Niefind
November 2015, The Biochemical journal,
Markus Pietsch, and Kaido Viht, and Alexander Schnitzler, and Ramesh Ekambaram, and Michaela Steinkrüger, and Erki Enkvist, and Christian Nienberg, and Anna Nickelsen, and Miriam Lauwers, and Joachim Jose, and Asko Uri, and Karsten Niefind
May 2013, ACS chemical biology,
Markus Pietsch, and Kaido Viht, and Alexander Schnitzler, and Ramesh Ekambaram, and Michaela Steinkrüger, and Erki Enkvist, and Christian Nienberg, and Anna Nickelsen, and Miriam Lauwers, and Joachim Jose, and Asko Uri, and Karsten Niefind
July 2013, ACS chemical biology,
Markus Pietsch, and Kaido Viht, and Alexander Schnitzler, and Ramesh Ekambaram, and Michaela Steinkrüger, and Erki Enkvist, and Christian Nienberg, and Anna Nickelsen, and Miriam Lauwers, and Joachim Jose, and Asko Uri, and Karsten Niefind
September 2012, Expert opinion on therapeutic patents,
Markus Pietsch, and Kaido Viht, and Alexander Schnitzler, and Ramesh Ekambaram, and Michaela Steinkrüger, and Erki Enkvist, and Christian Nienberg, and Anna Nickelsen, and Miriam Lauwers, and Joachim Jose, and Asko Uri, and Karsten Niefind
September 2015, Cellular and molecular life sciences : CMLS,
Markus Pietsch, and Kaido Viht, and Alexander Schnitzler, and Ramesh Ekambaram, and Michaela Steinkrüger, and Erki Enkvist, and Christian Nienberg, and Anna Nickelsen, and Miriam Lauwers, and Joachim Jose, and Asko Uri, and Karsten Niefind
January 1991, Journal of medicinal chemistry,
Markus Pietsch, and Kaido Viht, and Alexander Schnitzler, and Ramesh Ekambaram, and Michaela Steinkrüger, and Erki Enkvist, and Christian Nienberg, and Anna Nickelsen, and Miriam Lauwers, and Joachim Jose, and Asko Uri, and Karsten Niefind
October 2009, Bioorganic & medicinal chemistry,
Markus Pietsch, and Kaido Viht, and Alexander Schnitzler, and Ramesh Ekambaram, and Michaela Steinkrüger, and Erki Enkvist, and Christian Nienberg, and Anna Nickelsen, and Miriam Lauwers, and Joachim Jose, and Asko Uri, and Karsten Niefind
December 2008, Biochimica et biophysica acta,
Markus Pietsch, and Kaido Viht, and Alexander Schnitzler, and Ramesh Ekambaram, and Michaela Steinkrüger, and Erki Enkvist, and Christian Nienberg, and Anna Nickelsen, and Miriam Lauwers, and Joachim Jose, and Asko Uri, and Karsten Niefind
October 2008, Anti-cancer agents in medicinal chemistry,
Markus Pietsch, and Kaido Viht, and Alexander Schnitzler, and Ramesh Ekambaram, and Michaela Steinkrüger, and Erki Enkvist, and Christian Nienberg, and Anna Nickelsen, and Miriam Lauwers, and Joachim Jose, and Asko Uri, and Karsten Niefind
January 2021, Exploration of targeted anti-tumor therapy,
Copied contents to your clipboard!